PUMA BIOTECHNOLOGY, INC. (PBYI) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | after close | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "- Raising 2026 net income guidance" exhibit |
| Q3 FY2026 | "“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and 340B sales, as well as a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter,” said Alan H." exhibit |
| Q3 FY2026 | "Auerbach added, “We anticipate the following key milestones over the next 12 months: (i) presentation of updated data from ALISCA ® -Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (San Antonio Breast Cancer Symposium, December 2026); (ii) initiation of discussions with global regulatory agencies regarding the Phase III trial design for alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive m" exhibit |
| Q3 FY2026 | "The $3.5 million year-over-year increase in other income for the first nine months of 2026 resulted primarily from a decrease in interest expense, reflecting a lower debt balance, as Puma paid down its debt principal in May 2026, partially offset by the termination of subleases as of March 31, 2026 and unfavorable exchange rates on Euro-denominated transactions." exhibit |
| Q3 FY2026 | "Fourth Quarter and Full Year 2026 Financial Outlook" exhibit |
| Q2 FY2026 | "Raising 2026 Revenue and Net Income Guidance Based on" exhibit |
| Q2 FY2026 | "Auerbach added, “We anticipate the following key milestones over the next 12 months: (i) initiation of enrollment in ALISCA ® -Lung2, a Phase I/II trial of alisertib in combination with paclitaxel for the treatment of patients with extensive stage small cell lung cancer (Q3 2026); (ii) expansion of enrollment in ALISCA ® -Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (H2 2026); (iii) expansion of ALISCA ® -Lung1, a Phase II clinical trial of alisertib monothera" exhibit |
| Q2 FY2026 | "The $2.2 million year-over-year increase in other income for the first six months of 2026 resulted primarily from a decrease in interest expense, which reflects a lower debt balance as we paid down our debt principal in the three months ended June 30, 2026." exhibit |
| Q2 FY2026 | "Third Quarter and Full Year 2026 Financial Outlook" exhibit |
| Q2 FY2026 | "Puma Biotechnology will host a conference call to report its second quarter 2026 financial results and provide an update on its business and outlook at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 6, 2026 ." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PBYI
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PBYI
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/PBYI/"><img src="https://veritasdata.dev/embed/PBYI.svg" alt="PBYI earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/PBYI/)
Script
<script async src="https://veritasdata.dev/embed/PBYI.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PBYI"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.